HUTCHMED Reports Positive Results from SACHI Phase III Study of Savolitinib and Osimertinib in EGFR Mutation-Positive NSCLC

HUTCHMED's SACHI Phase III study of savolitinib plus osimertinib in advanced EGFR-mutant NSCLC showed a statistically significant improvement in progression-free survival (PFS) compared to chemotherapy, with a median PFS of 8.2 months versus 4.5 months (HR 0.34, p<0.0001). The combination also demonstrated a favorable safety profile, and a New Drug Application has been accepted and granted priority review in China; however, overall survival data is not yet mature, leaving some uncertainty regarding long-term efficacy. Institutional investor activity in HCM stock has been mixed, with some firms increasing and others decreasing their positions in Q1 2025.

Analysis

HUTCHMED's SACHI Phase III study results for its savolitinib plus osimertinib combination in treating advanced EGFR-mutant NSCLC with MET amplification represent a significant clinical development. The interim analysis demonstrated a marked improvement in median progression-free survival (PFS), with 8.2 months for the combination versus 4.5 months for chemotherapy (HR 0.34; p<0.0001) as assessed by investigators, and 7.2 months versus 4.2 months (HR 0.40; p<0.0001) per independent review. This efficacy, alongside an improved investigator-assessed objective response rate (58% vs 34%) and median duration of response (8.4 months vs 3.2 months), was coupled with a favorable safety profile, as Grade 3 or higher treatment-emergent adverse events occurred in an identical 57% of patients in both the combination and chemotherapy arms, with no new safety signals observed. The potential for a chemotherapy-free, all-oral regimen is a key advantage for patients. Crucially, these positive findings have led to the acceptance and granting of priority review for a New Drug Application by China's National Medical Products Administration (NMPA), positioning the combination for potential market entry. However, overall survival data remains immature, introducing an element of uncertainty regarding long-term benefits, a factor noted in the company's forward-looking statements. Institutional investor activity in HUTCHMED (HCM) during Q1 2025 was mixed; while 19 institutions increased their holdings, including notable additions by Jane Street Group (+124,771 shares, +128.0%) and BlackRock (+57,707 shares, +369.9%), 44 institutions reduced their positions, with significant decreases from UBS Group (-161,163 shares, -42.7%) and Millennium Management (-99,058 shares, -47.3%), reflecting a divergent near-term outlook among large investors despite the positive trial news.

Key Decisions for Investors

• Investors should closely monitor the maturation of overall survival data from the SACHI study and the NMPA's final regulatory decision on HUTCHMED's savolitinib-osimertinib combination, as these are critical upcoming catalysts for HCM.
• The statistically significant progression-free survival benefit (8.2 months vs 4.5 months with chemotherapy, investigator-assessed) and tolerable safety profile, coupled with its chemotherapy-free oral administration, suggest strong potential for this regimen in the indicated NSCLC population, which could significantly impact HUTCHMED's commercial prospects in China.
• The divergent institutional investor activity in HCM, with substantial Q1 2025 buying from firms like Jane Street and BlackRock contrasted by divestment from others such as UBS and Millennium Management, warrants careful consideration of individual risk appetite and further due diligence before altering positions in the stock.